BioGaia associated MetaboGen starts study on Intrahepatic Cholestasis of Pregnancy with Ferring
MetaboGen AB and Ferring Pharmaceuticals announce a research collaboration aimed at developing a microbiome-based product to prevent and treat Intrahepatic Cholestasis of Pregnancy (ICP). In December recruitment of patients for the first clinical trial begins. BioGaia holds 36 percent of the research company MetaboGen.MetaboGen has developed and patented a concept for how the microbiome (the overall expression of microbial genes) could affect intrahepatic cholestasis of pregnancy, a disorder affecting around 400,000 pregnant women annually. Recruitment of patients for the first